Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 55 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)Active, not recruitingNCT05038813Phase 2
- Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).Status unknownNCT05038657Phase 2
- Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.Status unknownNCT05036798Phase 2
- PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal CancerStatus unknownNCT05035381Phase 2
- Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung CancerStatus unknownNCT05034133Phase 2
- Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung CancerStatus unknownNCT05034055Phase 2
- Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDOActive, not recruitingNCT05033756Phase 2
- Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.Status unknownNCT05033587Phase 2
- A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical CancerWithdrawnNCT05033132Phase 2
- A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesActive, not recruitingNCT05032040Phase 2
- A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with CancersCompletedNCT05031494Phase 2
- Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal CancerStatus unknownNCT05030246Phase 2
- HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCCStatus unknownNCT05029973Phase 2
- A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN)Status unknownNCT05027204Phase 1/2
- A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT05026593Phase 1
- A Study Investigating AGEN1777 in Participants With Advanced Solid TumorsCompletedNCT05025085Phase 1
- Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell CarcinomaStatus unknownNCT05024266Phase 2
- Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME StudyWithdrawnNCT05022394Phase 1/2
- A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid TumoursCompletedNCT05021120Early Phase 1
- Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal CancerStatus unknownNCT05019534Phase 1
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)CompletedNCT05017012Phase 1
- TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.Status unknownNCT05013697Phase 2
- Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical CarcinomaStatus unknownNCT05013268Phase 1
- Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain MetastasesActive, not recruitingNCT05012254Phase 2
- Cryoablation Combined with Sintilimab Plus Lenvatinib in Patients with Advanced Intrahepatic CholangiocarcinomaCompletedNCT05010668Phase 2
- A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal CancerActive, not recruitingNCT05009069Phase 2
- Gut Microbiota Reconstruction for NSCLC ImmunotherapyStatus unknownNCT05008861Phase 1
- A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ AdenocarcinomaCompletedNCT05008783Phase 3
- Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLHStatus unknownNCT05008666Phase 2
- Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT05007613Phase 2
- PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT05007145Phase 2
- XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT05005728Phase 2
- A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.Status unknownNCT05005468Phase 2
- Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal MelanomaCompletedNCT05004025Phase 1
- Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular CarcinomaCompletedNCT05003700Phase 2
- Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung CancerActive, not recruitingNCT05003037Phase 2
- Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node MetastasisStatus unknownNCT05002686Phase 2/3
- Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based ChemotherapyCompletedNCT05001971Phase 2
- KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 AgentTerminatedNCT05001724Phase 2/3
- Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLCStatus unknownNCT05001412Phase 1
- Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line ImmunotherapyActive, not recruitingNCT05000710Phase 2
- Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1Status unknownNCT04999800Phase 2
- A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian CancerTerminatedNCT04999605Phase 1/2
- Axitinib + Ipilimumab in Advanced MelanomaActive, not recruitingNCT04996823Phase 2
- Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung CancerStatus unknownNCT04996771Phase 1/2
- Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)CompletedNCT04996758Phase 2
- ALPPS Combined With Tislelizumab in Liver MalignancyStatus unknownNCT04996446Phase 2
- A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCActive, not recruitingNCT04995523Phase 1/2
- Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell CarcinomaStatus unknownNCT04995016Phase 2
- Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II TrialStatus unknownNCT04992988Phase 2
- A Study of JNJ-78306358 in Participants With Advanced Stage Solid TumorsCompletedNCT04991740Phase 1
- A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid TumorsCompletedNCT04991506Phase 1
- Fruquintinib Plus PD-1 Antibody in pMMR / MSS Locally Advanced Rectal Cancer (LARC) With High Immune ScoreStatus unknownNCT04989855Phase 2
- Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLCStatus unknownNCT04989322Phase 2
- Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung CancerWithdrawnNCT04989283Phase 2
- TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular CarcinomaActive, not recruitingNCT04988945Phase 2
- Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal CancerStatus unknownNCT04988191Phase 1/2
- A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin LymphomasTerminatedNCT04986865Phase 1
- To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.Active, not recruitingNCT04985851Not applicable
- Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric CancerCompletedNCT04984733Phase 2
- Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 BlockadeStatus unknownNCT04984018Phase 2
- Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOCStatus unknownNCT04983550Phase 2
- Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric CancerStatus unknownNCT04982939Phase 2
- A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLCStatus unknownNCT04982549Phase 2
- A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical CancerActive, not recruitingNCT04982237Phase 3
- A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT04981899Phase 1/2
- A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative ResectionStatus unknownNCT04981665Phase 2
- Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of MelanomaStatus unknownNCT04979585Phase 2
- Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced TumorsStatus unknownNCT04979390Phase 1
- A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLCStatus unknownNCT04976647Phase 2
- Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)Active, not recruitingNCT04976634Phase 2
- First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical CancerTerminatedNCT04974944Phase 2
- A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical CancerStatus unknownNCT04974827Phase 2
- A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Phase 3
- Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical CancerStatus unknownNCT04973904Phase 2
- A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced MelanomaActive, not recruitingNCT04971499Phase 1/2
- Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003Status unknownNCT04970914Phase 2
- Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC TreatmentStatus unknownNCT04970043Not applicable
- Combination Immunotherapy in Rare Cancers Under InvesTigationActive, not recruitingNCT04969887Phase 2
- Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 MutationsStatus unknownNCT04969029Phase 2
- Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)Active, not recruitingNCT04968106Phase 2
- A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLCStatus unknownNCT04967625Phase 2
- Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic MelanomaTerminatedNCT04967196Phase 1
- Study of Nivolumab-Ipilimumab and cfDNA in Lung CancerTerminatedNCT04966676Phase 2
- Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver CancerWithdrawnNCT04965714Phase 2
- A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)Status unknownNCT04964479Phase 3
- A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid TumorStatus unknownNCT04964375Phase 1
- Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal CancerActive, not recruitingNCT04963283Phase 2
- Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapyActive, not recruitingNCT04962126Phase 2
- Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse CisplatinActive, not recruitingNCT04960709Phase 3
- Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary SyndromeActive, not recruitingNCT04960618Phase 2
- Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLCActive, not recruitingNCT04958811Phase 2
- Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 ExpressionActive, not recruitingNCT04957615Phase 2
- A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and NivolumabWithdrawnNCT04955262Phase 1
- TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)CompletedNCT04954794Phase 2
- Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic CancerCompletedNCT04953962Phase 2
- ARID1A and/or KDM6A Mutation and CXCL13 ExpressionActive, not recruitingNCT04953104Phase 2
- Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)TerminatedNCT04952571Phase 2
- Anlotinib or Penpulimab in Combination With RAI for DTCStatus unknownNCT04952493Phase 2
- A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLCStatus unknownNCT04950400Not applicable